Safety

News

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.

R&D

Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.

News

A California jury has awarded $40m in damages to two women who sued Johnson & Johnson, claiming that its talc products caused ovarian cancer.

News

Uncertainty ends Sarepta's Duchenne gene therapy Elevidys ends after an FDA label update, with the company's shares on the up despite restrictions.

News

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.

News

Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.